These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11322265)

  • 41. Drug combination shows benefits for AIDS patients with history of taking AZT.
    AIDS Patient Care STDS; 1996 Jun; 10(3):185-6. PubMed ID: 11361628
    [No Abstract]   [Full Text] [Related]  

  • 42. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
    Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.
    Campbell TB; Shulman NS; Johnson SC; Zolopa AR; Young RK; Bushman L; Fletcher CV; Lanier ER; Merigan TC; Kuritzkes DR
    Clin Infect Dis; 2005 Jul; 41(2):236-42. PubMed ID: 15983922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Study on mutations and antiretroviral therapy (SMART): preliminary results.
    Gianotti N; Moretti F; Tambussi G; Racca S; Presi S; Crucianelli R; Carrera P; Ferrari M; Lazzarin A
    Antivir Ther; 1999; 4 Suppl 3():65-9. PubMed ID: 16021873
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug resistance mutations during structured treatment interruptions.
    Yerly S; Fagard C; Günthard HF; Hirschel B; Perrin L;
    Antivir Ther; 2003 Oct; 8(5):411-5. PubMed ID: 14640388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients.
    Maxeiner HG; Keulen W; Schuurman R; Bijen M; de Graaf L; van Wijk A; Back N; Kline MW; Boucher CA; Nijhuis M
    J Infect Dis; 2002 Apr; 185(8):1070-6. PubMed ID: 11930317
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group.
    Holguín A; Dietrich U; Immelmann A; Soriano V
    Antivir Ther; 1998; 3(3):183-6. PubMed ID: 10682136
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
    Markowitz M; Vesanen M; Tenner-Racz K; Cao Y; Binley JM; Talal A; Hurley A; Jin X; Chaudhry MR; Yaman M; Frankel S; Heath-Chiozzi M; Leonard JM; Moore JP; Racz P; Nixon DF; Ho DD
    J Infect Dis; 1999 Mar; 179(3):527-37. PubMed ID: 9952358
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy.
    Devereux HL; Youle M; Johnson MA; Loveday C
    AIDS; 1999 Dec; 13(18):F123-7. PubMed ID: 10630517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction and maintenance treatment regimens for HIV-1 infection in vitro.
    Oh MD; Merrill DP; Hirsch MS
    Antivir Ther; 1999; 4(1):29-34. PubMed ID: 10682126
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.
    Harrigan PR; Stone C; Griffin P; Nájera I; Bloor S; Kemp S; Tisdale M; Larder B
    J Infect Dis; 2000 Mar; 181(3):912-20. PubMed ID: 10720512
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
    Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J; Merigan TC
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.
    Hanna GJ; Johnson VA; Kuritzkes DR; Richman DD; Brown AJ; Savara AV; Hazelwood JD; D'Aquila RT
    J Infect Dis; 2000 Mar; 181(3):904-11. PubMed ID: 10720511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo.
    van 't Wout AB; Ran LJ; Nijhuis M; Tijnagel JM; de Groot T; van Leeuwen R; Boucher CA; Schuitemaker H; Schuurman R
    AIDS; 1998 Jul; 12(10):1169-76. PubMed ID: 9677166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of antiretroviral therapy on hepatitis C viraemia in HIV-infected patients.
    Bravo R; Soriano V; García-Samaniego J; Gómez-Cano M; González-Lahoz J; Altisent C; Ruiz I
    Antivir Ther; 1996 Aug; 1(3):194. PubMed ID: 11322254
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficiency of drug resistance genotypic tests in specimens with low HIV viral load.
    Gómez-Cano M; Rubio A; Ruiz L; Pérez-Olmeda M; Leal M; Clotet B; Soriano V
    Antivir Ther; 1999; 4(2):123-4. PubMed ID: 10682158
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.
    Holodniy M; Katzenstein D; Mole L; Winters M; Merigan T
    J Infect Dis; 1996 Oct; 174(4):854-7. PubMed ID: 8843229
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells.
    Vesanen M; Markowitz M; Cao Y; Ho DD; Saksela K
    Virology; 1997 Sep; 236(1):104-9. PubMed ID: 9299622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.